NFKB1 and breast carcinoma: In keeping with this paradigm, our group recently demonstrated that systemic MTD chemotherapy of assorted agents, including paclitaxel, gemcitabine, doxorubicin, and cyclophosphamide, had profound impacts on CAFs in human breast cancer and PDAC tissues, which acquired the ability to secret large amounts of pro-stemness ELR+ CXCL chemokines through the chronic activation of STAT-1 and NF-κB signaling (37).